Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

Arthritis and Rheumatology

Volumn 69, Issue 1, 2017, Pages 148-160

  Furumoto, Yasuko ^a   Smith, Carolyne K ^b   Blanco, Luz ^b   Zhao, Wenpu ^b   Brooks, Stephen R ^b   Thacker, Seth G ^c   Zarzour, Abdalrahman ^c   Sciumè, Giuseppe ^b   Tsai, Wanxia L ^a   Trier, Anna M ^a   Nunez, Leti ^a   Mast, Laurel ^a   Hoffmann, Victoria ^b   Remaley, Alan T ^c   O'Shea, John J ^b   Kaplan, Mariana J ^b   Gadina, Massimo ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CHOLESTEROL ESTER; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 17; INTERLEUKIN 2; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; STAT1 PROTEIN; TOFACITINIB; TUMOR NECROSIS FACTOR; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BASOPHIL; CARDIOVASCULAR RISK; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DERMATITIS; DISEASE ACTIVITY; ENDOTHELIAL PROGENITOR CELL; EOSINOPHIL COUNT; EXTRACELLULAR TRAP; FEMALE; GENE EXPRESSION; GLOMERULONEPHRITIS; HEMOGLOBIN BLOOD LEVEL; IMMUNE COMPLEX DEPOSITION; INNATE IMMUNITY; KIDNEY TISSUE; LIPOPROTEIN METABOLISM; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MONOCYTE; MONONUCLEAR CELL; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VASCULAR DISEASE; VASODILATATION; ANIMAL; COMPLICATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; VASCULAR DISEASES;

ANIMALS; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; VASCULAR DISEASES;

EID: 85007309278     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39818     Document Type: Article

References (54)

1. Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol 2013;110:228–32.
2. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011;7:691–9.
3. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:339–47.
4. Eriksson C, Eneslatt K, Ivanoff J, Rantapää-Dahlqvist S, Sundqvist KG. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003;12:766–74.
5. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006;65:209–15.
6. Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 2014;66:1888–99.
7. Crow MK, Olferiev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296–305.
8. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331–7.
9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299–308.
10. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med 2013;64:249–63.
11. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015;66:311–28.
12. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014;57:5023–38.
13. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875–8.
14. Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs 2013;27:431–8.
15. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234–43.
16. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20:1043–9.
17. Okiyama N, Furumoto Y, Villarroel VA, Linton JT, Tsai WL, Gutermuth J, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol 2014;134:992–1000.
18. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457–69.
19. Sikorski K, Chmielewski S, Olejnik A, Wesoly JZ, Heemann U, Baumann M, et al. STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction. JAKSTAT 2012;1:241–9.
20. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:271694.
21. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243–69.
22. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198–215.
23. Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis 2015;74:2199–206.
24. Stock AD, Wen J, Doerner J, Herlitz LC, Gulinello M, Putterman C. Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice. J Neuroinflammation 2015;12:205.
25. Yiu G, Rasmussen TK, Ajami B, Haddon DJ, Chu AD, Tangsombatvisit S, et al. Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding STAT-1. Arthritis Rheumatol 2016;68:1233–44.
26. Dema B, Charles N, Pellefigues C, Ricks TK, Suzuki R, Jiang C, et al. Immunoglobulin E plays an immunoregulatory role in lupus. J Exp Med 2014;211:2159–68.
27. Cates AM, Holden VI, Myers EM, Smith CK, Kaplan MJ, Kahlenberg JM. Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors. Rheumatology (Oxford) 2015;54:1114–23.
28. Tanaka H, Ikehara S, Furukawa F, Sekita K, Nakamura T, Inoue S, et al. The relationship between murine lupus nephritis and thymic abnormalities. Nihon Jinzo Gakkai Shi 1984;26:1069–77. In Japanese.
29. Horiguchi Y, Furukawa F, Hamashima Y, Imamura S. Ultrastructural lupus band test in the skin of MRL mice. Arch Dermatol Res 1986;278:474–80.
30. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009;183:3160–9.
31. Yokoyama S, Perera PY, Terawaki S, Watanabe N, Kaminuma O, Waldmann TA, et al. Janus kinase inhibitor tofacitinib shows potent efficacy in a mouse model of Autoimmune Lymphoproliferative Syndrome (ALPS). J Clin Immunol 2015;35:661–7.
32. Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012;8:183–9.
33. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, et al. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907–15.
34. Mohan S, Barsalou J, Bradley TJ, Slorach C, Reynolds JA, Hasni S, et al. Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2015;67:2257–62.
35. Rousvoal G, Si MS, Lau M, Zhang S, Berry GJ, Flores MG, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006;19:1014–21.
36. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67:616–25.
37. Quah HS, Miranda-Hernandez S, Khoo A, Harding A, Fynch S, Elkerbout L, et al. Deficiency in type I interferon signaling prevents the early interferon-induced gene signature in pancreatic islets but not type 1 diabetes in NOD mice. Diabetes 2014;63:1032–40.
38. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. Proc Natl Acad Sci U S A 2001;98:15137–42.
39. Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 2015;151:1110–2
40. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:201–11.
41. Crispin JC, Oukka M, Bayliss G, Cohen RA, van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008;181:8761–6.
42. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385–93.
43. Edgerton C, Crispin JC, Moratz CM, Bettelli E, Oukka M, Simovic M, et al. IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clin Immunol 2009;130:313–21.
44. Boggio E, Clemente N, Mondino A, Cappellano G, Orilieri E, Gigliotti CL, et al. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood 2014;123:1178–86.
45. Usui F, Kimura H, Ohshiro T, Tatsumi K, Kawashima A, Nishiyama A, et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012;420:72–7.
46. Kirou KA, Gkrouzman E. Anti-interferon α treatment in SLE. Clin Immunol 2013;148:303–12.
47. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338–46.
48. Knight JS, Zhao W, Luo W, Subramanian V, O'Dell AA, Yalavarthi S, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest 2013;123:2981–93.
49. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012;64:2975–85.
50. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010;184:3284–97.
51. Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2014;73:609–15.
52. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842–5.
53. Thacker SG, Rousset X, Esmail S, Zarzour A, Jin X, Collins HL, et al. Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice. J Lipid Res 2015;56:1282–95.
54. Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008;99:1265–73.